Notably, targeting of the CXCL10/CXCR3 axis in addition to cardiac inflammation may constitute a new pharmacological approach for either heart failure or CAD therapy supplementary to present drugs that typically target the sympathetic or renin-angiotensin system or platelets [119]. Here, REN is linked to coronary artery disorder.